|
US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US7247453B1
(en)
*
|
1988-12-30 |
2007-07-24 |
Oklahoma Medical Research Foundation |
Calcium binding recombinant antibody against protein C
|
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
|
US20030225254A1
(en)
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
|
DE69027121T3
(de)
|
1989-08-07 |
2001-08-30 |
Peptech Ltd., Dee Why |
Bindeligande für tumornekrosisfaktor
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
GR1001050B
(el)
*
|
1990-01-09 |
1993-04-28 |
Protein Design Labs Inc |
Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
GB9020282D0
(en)
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
|
US5858725A
(en)
*
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
|
WO1992015683A1
(en)
*
|
1991-03-06 |
1992-09-17 |
MERCK Patent Gesellschaft mit beschränkter Haftung |
Humanized and chimeric monoclonal antibodies
|
|
IL101147A
(en)
*
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
CA2107553C
(en)
*
|
1991-04-05 |
2001-07-31 |
Nancy Lin |
Monoclonal antibodies to stem cell factor receptors
|
|
TW205553B
(no)
*
|
1991-04-25 |
1993-05-11 |
Chugai Pharmaceutical Co Ltd |
|
|
DE69233482T2
(de)
*
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115010D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
BR9206310A
(pt)
*
|
1991-07-25 |
1995-04-25 |
Idec Pharma Corp |
Indução de respostas citotóxicas de linfócitos T.
|
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
|
MX9204374A
(es)
*
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
US6699472B2
(en)
|
1991-08-14 |
2004-03-02 |
Genentech, Inc. |
Method of treating allergic disorders
|
|
US6329509B1
(en)
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
|
ES2145004T3
(es)
*
|
1991-08-21 |
2000-07-01 |
Novartis Ag |
Derivados de anticuerpos.
|
|
GB9120467D0
(en)
*
|
1991-09-26 |
1991-11-06 |
Celltech Ltd |
Anti-hmfg antibodies and process for their production
|
|
JP3024311B2
(ja)
*
|
1991-10-03 |
2000-03-21 |
味の素株式会社 |
Ｉｌ−２受容体重鎖に結合するポリペプチド
|
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
|
US5474771A
(en)
*
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
|
US5817310A
(en)
*
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
|
JPH05244982A
(ja)
*
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
ATE249840T1
(de)
*
|
1991-12-13 |
2003-10-15 |
Xoma Corp |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5777085A
(en)
*
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
|
DE69334255D1
(de)
*
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
|
GB9203459D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5714350A
(en)
*
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5387676A
(en)
*
|
1992-03-11 |
1995-02-07 |
Ciba Corning Diagnostics Corp. |
MN gene and protein
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US6129914A
(en)
*
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
|
US5874082A
(en)
*
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
GB9223377D0
(en)
*
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
|
DE69303494T2
(de)
*
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
DK0669986T3
(da)
*
|
1992-11-13 |
2003-07-28 |
Idec Pharma Corp |
Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
|
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5648267A
(en)
*
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
|
US5804187A
(en)
*
|
1992-11-16 |
1998-09-08 |
Cancer Research Fund Of Contra Costa |
Modified antibodies with human milk fat globule specificity
|
|
SG44845A1
(en)
|
1993-01-12 |
1997-12-19 |
Biogen Inc |
Recombitant anti-vla4 antibody molecules
|
|
US5951983A
(en)
*
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
|
US5817311A
(en)
*
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
|
US5730979A
(en)
*
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
WO1994025067A1
(en)
*
|
1993-05-04 |
1994-11-10 |
Cytel Corporation |
Antibodies to p-selectin and their uses
|
|
CA2163976C
(en)
*
|
1993-05-28 |
2010-06-29 |
Didier J. Leturcq |
Methods and compositions for inhibiting cd14 mediated cell activation
|
|
US5856135A
(en)
*
|
1993-05-31 |
1999-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human antibody to human interleukin-6
|
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
RU2162711C2
(ru)
*
|
1993-09-07 |
2001-02-10 |
Смитклайн Бичам Корпорейшн |
Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
|
|
PL180125B1
(pl)
*
|
1993-09-07 |
2000-12-29 |
Smithkline Beecham Corp |
Bialko fuzyjne o swoistosci wiazania przeciwko ludzkiej IL-4, PL PL PL PL PL PL
|
|
WO1995014041A1
(en)
|
1993-11-19 |
1995-05-26 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human medulloblastomatous cell
|
|
WO1995015181A1
(en)
*
|
1993-11-30 |
1995-06-08 |
Protein Design Labs, Inc. |
Reperfusion therapy using antibodies to l-selectin
|
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
AU703152B2
(en)
*
|
1994-01-25 |
1999-03-18 |
Biogen Ma Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
|
NZ282849A
(en)
|
1994-03-29 |
1998-05-27 |
Celltech Therapeutics Ltd |
Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region
|
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
|
US5622701A
(en)
*
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
|
US6048972A
(en)
*
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
|
DE4425115A1
(de)
*
|
1994-07-15 |
1996-01-18 |
Boehringer Mannheim Gmbh |
Verfahren zur Modifizierung der Stabilität von Antikörpern
|
|
EP0696455A1
(en)
*
|
1994-08-11 |
1996-02-14 |
Cellena (Cell Engineering) A.G. |
Transferrin compositions to alleviate the side effects of cytotoxic drugs
|
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
|
US5707621A
(en)
*
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
US5683892A
(en)
*
|
1994-12-23 |
1997-11-04 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
|
AU6171196A
(en)
*
|
1995-06-07 |
1996-12-30 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of ta99
|
|
US6001358A
(en)
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
|
GB9600660D0
(en)
|
1996-01-12 |
1996-03-13 |
Ciba Geigy Ag |
Protein
|
|
US6046310A
(en)
*
|
1996-03-13 |
2000-04-04 |
Protein Design Labs., Inc. |
FAS ligand fusion proteins and their uses
|
|
US5882644A
(en)
*
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
|
US6713305B1
(en)
|
1996-04-29 |
2004-03-30 |
Novartis Ag |
Metastasis-associated antigen and antibodies thereto
|
|
ATE248192T1
(de)
|
1996-06-07 |
2003-09-15 |
Neorx Corp |
HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
|
|
US6534311B2
(en)
|
1996-07-24 |
2003-03-18 |
Novartis Ag |
Drosophila melanogaster p70S6 kinase
|
|
US6833255B1
(en)
|
1996-07-24 |
2004-12-21 |
Novartis, Ag |
Drosophila melanogaster p70 S6 kinase
|
|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
AU725329B2
(en)
*
|
1996-09-02 |
2000-10-12 |
Ko Okumura |
Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
|
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
|
KR100847441B1
(ko)
*
|
1996-09-26 |
2008-07-21 |
츄가이 세이야꾸 가부시키가이샤 |
인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
|
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
|
US20020160005A1
(en)
|
1996-11-15 |
2002-10-31 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic urmec syndrome
|
|
DE951551T1
(de)
|
1996-12-23 |
2000-09-14 |
Immunex Corp., Seattle |
Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
|
|
US6262238B1
(en)
*
|
1997-01-14 |
2001-07-17 |
Roche Diagnostic, Gmbh |
Process for modifying the stability of antibodies
|
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US20030109680A1
(en)
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US20060235209A9
(en)
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
|
IL123756A0
(en)
*
|
1997-03-21 |
1998-10-30 |
Sankyo Co |
Humanized anti-human FAS antibody
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
WO1998045331A2
(en)
|
1997-04-07 |
1998-10-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20020165363A1
(en)
*
|
1997-05-15 |
2002-11-07 |
Koh Sato |
Cachexia remedy
|
|
ATE319745T1
(de)
*
|
1997-05-21 |
2006-03-15 |
Biovation Ltd |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
|
WO1999017798A1
(en)
|
1997-10-02 |
1999-04-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
CN1277632A
(zh)
|
1997-10-03 |
2000-12-20 |
中外制药株式会社 |
天然人源化抗体
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
EP1745799B1
(en)
|
1998-03-04 |
2015-09-02 |
The Trustees of The University of Pennsylvania |
Compositions and methods of treating tumors
|
|
ATE512225T1
(de)
|
1998-04-03 |
2011-06-15 |
Chugai Pharmaceutical Co Ltd |
Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
|
|
KR101063278B1
(ko)
|
1998-08-11 |
2011-09-07 |
바이오겐 아이덱 인크. |
Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
|
|
JP4689781B2
(ja)
*
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
|
ES2319831T3
(es)
|
1998-09-14 |
2009-05-12 |
Board Of Regents, The University Of Texas System |
Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
|
|
CN1230546C
(zh)
|
1998-10-06 |
2005-12-07 |
马克·阿龙·埃马尔法尔布 |
丝状真菌宿主领域的转化系统
|
|
DE69839740D1
(de)
|
1998-10-22 |
2008-08-28 |
Univ Montana |
Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
|
|
EP1131093A4
(en)
|
1998-11-09 |
2002-05-02 |
Idec Pharma Corp |
TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
|
|
GB9825632D0
(en)
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
WO2000051628A2
(en)
|
1999-03-03 |
2000-09-08 |
Biogen, Inc. |
Methods of modulating lipid metabolism and storage
|
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
|
DE60020955T2
(de)
|
1999-04-22 |
2006-05-11 |
Biogen Idec Ma Inc., Cambridge |
Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit
|
|
IT1306704B1
(it)
*
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
|
GEP20063774B
(en)
|
1999-06-01 |
2006-03-27 |
Biogen Idec Inc |
Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
DE60038252T2
(de)
*
|
1999-09-30 |
2009-03-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
WO2001043774A1
(en)
|
1999-12-16 |
2001-06-21 |
Biogen, Inc. |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
|
DK1265928T3
(da)
|
2000-01-27 |
2010-11-15 |
Medimmune Llc |
RSV-neutraliserende antistoffer med ultra høj affinitet
|
|
CA2399080C
(en)
*
|
2000-02-03 |
2013-05-21 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-ccr2 antibodies and methods of use therefor
|
|
AU3495301A
(en)
|
2000-02-11 |
2001-08-20 |
Biogen Inc |
Heterologous polypeptide of the tnf family
|
|
DE1257584T1
(de)
|
2000-02-24 |
2003-05-28 |
Lilly Co Eli |
Humanisierte antikörper, die amyloid beta peptid demarkieren
|
|
EP2341075A1
(en)
|
2000-03-01 |
2011-07-06 |
MedImmune, LLC |
Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
|
|
EP1267926A2
(en)
|
2000-03-17 |
2003-01-02 |
Millennium Pharmaceuticals, Inc. |
Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
|
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
|
AU2001252618A1
(en)
|
2000-04-28 |
2001-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
ATE412185T1
(de)
|
2000-04-29 |
2008-11-15 |
Univ Iowa Res Found |
Diagnostika und therapeutika für makula degeneration erkrankungen
|
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
|
GB0013810D0
(en)
*
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
|
DE60143535D1
(de)
|
2000-10-02 |
2011-01-05 |
Novartis Vaccines & Diagnostic |
Humane antikörper gegen cd40
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
CN1296386C
(zh)
*
|
2001-04-06 |
2007-01-24 |
布里斯托尔大学 |
Cd25结合分子在类固醇耐受型患者中的用途
|
|
BRPI0209792B8
(pt)
|
2001-04-13 |
2021-05-25 |
Biogen Idec Inc |
anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina
|
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
|
CZ20033476A3
(cs)
*
|
2001-05-18 |
2004-05-12 |
Boehringeráingelheimáinternationalágmbh |
Protilátky specifické pro CD@@v
|
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
|
JP4675512B2
(ja)
*
|
2001-07-10 |
2011-04-27 |
三井化学株式会社 |
熱殺菌方法
|
|
JP2005522192A
(ja)
|
2001-07-19 |
2005-07-28 |
パーラン セラピューティクス， インコーポレイテッド |
マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
|
|
JP4729717B2
(ja)
†
|
2001-08-03 |
2011-07-20 |
株式会社医学生物学研究所 |
ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
|
|
US7771722B2
(en)
|
2001-08-17 |
2010-08-10 |
Eli Lilly And Company |
Assay method for alzheimer's disease
|
|
PL232477B1
(pl)
|
2001-09-20 |
2019-06-28 |
Immunex Corp |
System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu
|
|
CA2461529A1
(en)
|
2001-09-25 |
2003-04-03 |
Immuno-Biological Laboratories Co., Ltd. |
Recombinant anti-osteopontin antibody and use thereof
|
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
|
PL369739A1
(en)
*
|
2001-11-12 |
2005-05-02 |
Merck Patent Gmbh |
Modified anti-tnf alpha antibody
|
|
EP1944043A1
(en)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
|
HU230364B1
(hu)
|
2001-11-21 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
|
|
DK1461300T3
(da)
|
2001-11-30 |
2011-10-24 |
Biogen Idec Inc |
Antistoffer mod kemotaktiske monocytproteiner
|
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
|
PT1461428E
(pt)
|
2001-12-03 |
2012-05-29 |
Alexion Pharma Inc |
Método para produção de anticorpos híbridos
|
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
|
EP2295468B1
(en)
*
|
2002-02-14 |
2015-07-08 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
|
CN1780907B
(zh)
*
|
2002-02-22 |
2011-06-15 |
原基因药物有限公司 |
抗ccr5抗体
|
|
KR20040105740A
(ko)
|
2002-02-25 |
2004-12-16 |
엘란 파마슈티칼스, 인크. |
염증 치료제의 투여 방법
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
MY147019A
(en)
|
2002-03-13 |
2012-10-15 |
Biogen Idec Inc |
Anti-alpha v beta 6 antibodies
|
|
DK1495056T3
(da)
|
2002-03-20 |
2011-05-02 |
Ucb Pharma Sa |
Fremgangsmåde til analyse af antistofdisulfidisomere
|
|
JP4432031B2
(ja)
|
2002-03-22 |
2010-03-17 |
ズィナイス オペレーションズ ピーティーワイ．エルティーディー． |
インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
DE60333285D1
(de)
|
2002-05-14 |
2010-08-19 |
Martek Biosciences Corp |
Carotinsynthase-gen und dessen verwendung
|
|
ATE518885T1
(de)
|
2002-05-28 |
2011-08-15 |
Ucb Pharma Sa |
Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
|
|
WO2003101485A1
(en)
*
|
2002-05-30 |
2003-12-11 |
Macrogenics, Inc. |
Cd16a binding proteins and use for the treatment of immune disorders
|
|
AU2002319236A1
(en)
|
2002-06-14 |
2003-12-31 |
Monier Tadros |
Method for the production of protamine
|
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
WO2004002500A1
(en)
|
2002-06-28 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
|
BRPI0316282B8
(pt)
|
2002-11-15 |
2021-05-25 |
Genmab As |
anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão
|
|
EP2363410B1
(en)
|
2002-11-27 |
2017-10-11 |
Minerva Biotechnologies Corporation |
Isoforms of MUC1
|
|
CN103833854B
(zh)
|
2002-12-16 |
2017-12-12 |
健泰科生物技术公司 |
免疫球蛋白变体及其用途
|
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
SK50642005A3
(sk)
|
2003-01-24 |
2006-02-02 |
Elan Pharmaceuticals, Inc. |
Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
|
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
|
MXPA05011409A
(es)
|
2003-04-23 |
2005-12-12 |
Medarex Inc |
Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal.
|
|
CN1795010A
(zh)
|
2003-04-23 |
2006-06-28 |
梅达雷克斯公司 |
针对α干扰素受体－1(IFNAR－1)的人源化抗体
|
|
ES2640669T3
(es)
|
2003-05-19 |
2017-11-03 |
Prothena Biosciences Limited |
Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
|
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
|
NZ544486A
(en)
|
2003-06-13 |
2009-04-30 |
Biogen Idec Inc |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
|
AU2004259638C1
(en)
|
2003-07-08 |
2018-12-20 |
Novartis Pharma Ag |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
|
TW201319088A
(zh)
|
2003-07-18 |
2013-05-16 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
|
CA2545166A1
(en)
*
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
|
US7361503B2
(en)
|
2003-11-12 |
2008-04-22 |
Albert Einstein College Of Medicine Of Yeshiva University |
Sequences encoding hepatitis C virus glycoproteins
|
|
DE602004020266D1
(de)
|
2003-12-05 |
2009-05-07 |
Multimmune Gmbh |
Therapeutische und diagnostische anti-hsp 70-antikörper
|
|
EP1692177A2
(en)
|
2003-12-08 |
2006-08-23 |
Morphotek, Inc. |
Antibodies that specifically bind pms2
|
|
EP2241331A3
(en)
|
2003-12-15 |
2011-03-09 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
|
US20070280950A1
(en)
|
2004-01-19 |
2007-12-06 |
Medical And Biological Laboratories Co., Ltd. |
Inflammatory Cytokine Inhibitors
|
|
WO2005081783A2
(en)
|
2004-01-30 |
2005-09-09 |
Dana Farber Cancer Institute |
Method for determination and quantification of radiation or genotoxin exposure
|
|
PL1713503T3
(pl)
|
2004-02-10 |
2014-02-28 |
Univ Colorado Regents |
Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
|
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
TWI359026B
(en)
|
2004-02-12 |
2012-03-01 |
Sankyo Co |
Pharmaceutical composition for the osteoclast rela
|
|
EP1717250A4
(en)
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
MONOCLONAL ANTIBODY AND ITS USE
|
|
JP4960859B2
(ja)
|
2004-03-12 |
2012-06-27 |
バスジーン セラピューティクス，インコーポレイテッド |
血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
|
HRP20130782T1
(en)
|
2004-04-02 |
2013-09-30 |
The Regents Of The University Of California, Office Of Technology Transfer |
Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
|
|
EP1761784B1
(en)
|
2004-05-24 |
2016-10-26 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
|
PT1781705E
(pt)
|
2004-06-21 |
2014-12-23 |
Medarex Llc |
Anticorpos contra recetor i do interferão alfa e as suas utilizações
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
JP5102028B2
(ja)
|
2004-07-26 |
2012-12-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗ｃｄ１５４抗体
|
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
|
JP2008520186A
(ja)
|
2004-10-01 |
2008-06-19 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
|
|
PL3428191T3
(pl)
|
2004-10-06 |
2025-04-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
|
CA2584211C
(en)
|
2004-10-22 |
2014-07-08 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
|
NZ554725A
(en)
|
2004-10-25 |
2009-10-30 |
Merck & Co Inc |
Anti-ADDL antibodies and uses thereof
|
|
CN101102792A
(zh)
|
2004-11-19 |
2008-01-09 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
PL1699826T3
(pl)
|
2005-01-05 |
2009-08-31 |
F Star Biotechnologische Forschungs Und Entw M B H |
Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
|
|
BRPI0607374B8
(pt)
|
2005-01-27 |
2021-05-25 |
Childrens Hospital & Res Center At Oakland |
vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
|
|
NZ595305A
(en)
|
2005-02-14 |
2013-06-28 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
DK2332408T3
(da)
|
2005-02-17 |
2013-12-02 |
Biogen Idec Inc |
Behandling af neurologiske sygdomme
|
|
WO2006090750A1
(ja)
|
2005-02-28 |
2006-08-31 |
Institute For Antibodies Co., Ltd. |
抗IgSF4抗体及びその利用
|
|
BRPI0608254A2
(pt)
|
2005-03-02 |
2009-12-08 |
Biogen Idec Inc |
anticorpos kim-1 para o tratamento de condições mediadas por th2
|
|
AU2006223301B2
(en)
|
2005-03-10 |
2010-11-04 |
Eisai, Inc. |
Anti-mesothelin antibodies
|
|
JP2008532559A
(ja)
|
2005-03-19 |
2008-08-21 |
メディカル リサーチ カウンシル |
ウイルス感染の治療及び予防又は治療及び予防の改善
|
|
EP1866339B8
(en)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Gitr binding molecules and uses therefor
|
|
JP2008543276A
(ja)
|
2005-03-30 |
2008-12-04 |
ミネルバ バイオテクノロジーズ コーポレーション |
Ｍｕｃ１発現細胞の増殖
|
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
|
WO2006105511A1
(en)
|
2005-03-31 |
2006-10-05 |
The General Hospital Corporation |
Monitoring and modulating hgf/hgfr activity
|
|
RS56418B2
(sr)
|
2005-04-04 |
2025-01-31 |
Biogen Ma Inc |
Metodi evaluacije imunskog odgovora na terapijsko sredstvo
|
|
EP2172487A1
(en)
|
2005-04-22 |
2010-04-07 |
Morphotek Inc. |
Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
|
|
AU2006241235B2
(en)
|
2005-04-22 |
2012-04-05 |
Eisai, Inc. |
Antibodies with immune effector activity and that internalize in endosialin-positive cells
|
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
WO2006117782A2
(en)
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
|
ME02461B
(me)
|
2005-05-10 |
2017-02-20 |
Incyte Holdings Corp |
Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
|
|
US7964200B2
(en)
|
2005-05-18 |
2011-06-21 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for immunizing against Chlamydia infection
|
|
AU2006247039B2
(en)
|
2005-05-19 |
2011-03-03 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
EP1885398B1
(en)
|
2005-05-26 |
2015-07-08 |
The Regents of the University of Colorado, a body corporate |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
CN102441163A
(zh)
|
2005-05-27 |
2012-05-09 |
比奥根艾迪克Ma公司 |
结合tweak的抗体
|
|
US8354106B2
(en)
|
2005-06-16 |
2013-01-15 |
The Feinstein Institute For Medical Research |
Antibodies against HMGB1 and fragments thereof
|
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
PT1899378E
(pt)
*
|
2005-06-21 |
2010-01-26 |
Xoma Technology Ltd |
Anticorpos de ligação de il-1β e os seus fragmentos
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
EP1910573B1
(en)
|
2005-07-22 |
2013-09-04 |
CytoDyn, Inc. |
Methods for reducing viral load in hiv-1-infected patients
|
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
JP5457671B2
(ja)
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
|
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
|
WO2007035930A2
(en)
|
2005-09-22 |
2007-03-29 |
Prosci Incorporated |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
|
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
US20090155279A1
(en)
|
2005-10-28 |
2009-06-18 |
Jiro Tanaka |
Pseudomonas Aeruginosa Outer Membrane Protein PA5158
|
|
TWI424161B
(zh)
|
2005-11-01 |
2014-01-21 |
Abbvie Biotechnology Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
CA2627446A1
(en)
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono S.A. |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
CN101506236B
(zh)
†
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
|
AU2007217563A1
(en)
|
2006-02-22 |
2007-08-30 |
University Of Zurich |
Methods for treating autoimmune or demyelinating diseases
|
|
CA2646478A1
(en)
|
2006-03-10 |
2007-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both il-17a and il-17f and methods of using the same
|
|
JP5082104B2
(ja)
|
2006-03-23 |
2012-11-28 |
国立大学法人東北大学 |
高機能性二重特異性抗体
|
|
US8084044B2
(en)
|
2006-03-30 |
2011-12-27 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein PA0427
|
|
WO2007117490A2
(en)
|
2006-04-05 |
2007-10-18 |
Abbott Biotechnology Ltd. |
Antibody purification
|
|
EP2708242A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of ankylosing spondylitis
|
|
EP2007426A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
EP2034830B1
(en)
|
2006-05-25 |
2014-09-03 |
Biogen Idec MA Inc. |
Anti-vla-1 antibody for treating stroke
|
|
ATE553130T1
(de)
|
2006-05-31 |
2012-04-15 |
Astellas Pharma Inc |
Humanisierter anti-human-osteopontin-antikörper
|
|
EP2035448A4
(en)
|
2006-06-01 |
2010-11-03 |
Elan Pharm Inc |
NEUROACTIVE FRAGMENTS OF APP
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
WO2008094176A2
(en)
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
CA2656771A1
(en)
|
2006-07-07 |
2008-01-10 |
Intercell Ag |
Small streptococcus pyogenes antigens and their use
|
|
CN101563105B
(zh)
|
2006-07-10 |
2013-01-23 |
拜奥根Idec马萨诸塞公司 |
用于抑制smad4-缺陷癌症的组合物和方法
|
|
EP2975057A1
(en)
|
2006-07-10 |
2016-01-20 |
Fujita Health University |
Novel anti-cd73 antibody
|
|
KR101437188B1
(ko)
|
2006-08-04 |
2014-10-02 |
노바르티스 아게 |
Ｅｐｈｂ3-특이적 항체 및 이의 용도
|
|
EP2056709A4
(en)
|
2006-08-11 |
2013-05-01 |
Univ New Jersey Med |
DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
|
|
EA201201533A1
(ru)
|
2006-08-18 |
2014-11-28 |
Новартис Аг |
Prlr-специфическое антитело и его применения
|
|
CA2842964A1
(en)
|
2006-09-13 |
2008-03-20 |
Abbvie Inc. |
Cell culture improvements
|
|
EP2500414A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Ａｄｃｃ活性を増強させた抗体及びその製造方法
|
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
|
CA2668295A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
|
KR101512203B1
(ko)
|
2006-11-10 |
2015-04-15 |
가부시키가이샤 리부텍쿠 |
ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
|
|
AU2007321817A1
(en)
|
2006-11-17 |
2008-05-22 |
Novartis Ag |
Lingo binding molecules and pharmaceutical use thereof
|
|
EP1923069A1
(en)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
|
US8288110B2
(en)
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
|
EP2505651A3
(en)
|
2006-12-10 |
2013-01-09 |
Dyadic International, Inc. |
Isolated fungus with reduced protease activity
|
|
US8440185B2
(en)
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
|
AU2007339773B2
(en)
|
2006-12-27 |
2011-03-10 |
The Johns Hopkins University |
Compositions and methods for stimulating an immune response
|
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
|
CN101646781B
(zh)
|
2006-12-29 |
2016-06-22 |
科罗拉多大学董事会 |
自身免疫病的诊断和治疗靶标及其用途
|
|
ES2439490T3
(es)
|
2007-01-05 |
2014-01-23 |
University Of Zurich |
Anticuerpo anti-beta amiloide y usos del mismo
|
|
AU2008204471B2
(en)
|
2007-01-12 |
2013-02-21 |
Intercell Ag |
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
|
|
EP2114983B8
(en)
|
2007-02-07 |
2015-02-18 |
The Regents of the University of Colorado, A Body Corporate |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
|
EP2130044B1
(en)
|
2007-02-16 |
2016-10-26 |
Genzyme Corporation |
Method of identifying risk for thyroid disorder
|
|
JP5558834B2
(ja)
|
2007-02-23 |
2014-07-23 |
ヤンセン アルツハイマー イミュノセラピー |
シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
|
|
JP2010519256A
(ja)
|
2007-02-23 |
2010-06-03 |
ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク |
免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
|
|
ES2546863T3
(es)
|
2007-02-23 |
2015-09-29 |
Prothena Biosciences Limited |
Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
|
|
DK2457928T3
(en)
|
2007-03-13 |
2017-08-28 |
Univ Zuerich |
Monoclonal human tumor-specific antibody
|
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
MX2009010701A
(es)
|
2007-04-05 |
2010-01-20 |
Morphotek Inc |
Metodos para inhibir la union de endosialina a ligandos.
|
|
CA2683145C
(en)
|
2007-04-27 |
2018-06-12 |
Katherine E. Lewis |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
|
EP2360177A1
(en)
|
2007-05-02 |
2011-08-24 |
Intercell AG |
Klebsiella antigens
|
|
EP2160403B1
(en)
|
2007-05-11 |
2018-08-08 |
Genzyme Corporation |
Methods of producing a secreted protein
|
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
BRPI0814252B8
(pt)
|
2007-06-14 |
2021-05-25 |
Biogen Idec Inc |
composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
|
|
US20100203075A1
(en)
|
2007-06-18 |
2010-08-12 |
Intercell Ag |
Chlamydia antigens
|
|
ES2975748T3
(es)
|
2007-06-26 |
2024-07-12 |
F Star Therapeutics Ltd |
Presentación de agentes de unión
|
|
KR101560843B1
(ko)
|
2007-06-27 |
2015-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
|
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
EP2175884B8
(en)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
|
CA2693707A1
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
|
CN101848998B
(zh)
|
2007-08-30 |
2016-08-03 |
第一三共株式会社 |
抗epha2抗体
|
|
EP2186892A1
(en)
*
|
2007-09-06 |
2010-05-19 |
Osaka University |
Anti-cd20 monoclonal antibodies
|
|
WO2009033071A2
(en)
|
2007-09-07 |
2009-03-12 |
Dyadic International, Inc. |
Novel fungal enzymes
|
|
US20100239570A1
(en)
|
2007-09-13 |
2010-09-23 |
Roger Nitsch |
Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
|
|
JP5963341B2
(ja)
|
2007-09-14 |
2016-08-10 |
アムジエン・インコーポレーテツド |
均質な抗体集団
|
|
SG10201605897RA
(en)
|
2007-10-11 |
2016-09-29 |
Daiichi Sankyo Co Ltd |
ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
CN101965365A
(zh)
|
2007-10-19 |
2011-02-02 |
伊缪纳斯制药株式会社 |
能够特异性结合Aβ寡聚体的抗体及其应用
|
|
CA2704447A1
(en)
|
2007-11-01 |
2009-05-07 |
University Of Iowa Research Foundation |
Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
|
|
PL2207808T3
(pl)
|
2007-11-02 |
2013-11-29 |
Novartis Ag |
Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne
|
|
WO2009062112A2
(en)
|
2007-11-09 |
2009-05-14 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as antimicrobials
|
|
SG10201405835TA
(en)
|
2007-11-12 |
2014-10-30 |
U3 Pharma Gmbh |
Axl antibodies
|
|
KR101614369B1
(ko)
|
2007-11-28 |
2016-04-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용
|
|
CA2706258C
(en)
|
2007-11-28 |
2017-06-06 |
The Trustees Of The University Of Pennsylvania |
Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
|
|
WO2009079242A2
(en)
|
2007-12-05 |
2009-06-25 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
|
WO2009078799A1
(en)
|
2007-12-17 |
2009-06-25 |
Marfl Ab |
New vaccine for the treatment of mycobacterium related disorders
|
|
WO2009081955A1
(ja)
|
2007-12-25 |
2009-07-02 |
Meiji Seika Kaisha, Ltd. |
緑膿菌のiii型分泌装置構成タンパク質pa1698
|
|
EA028356B1
(ru)
|
2007-12-28 |
2017-11-30 |
Протена Байосайенсиз Лимитед |
Лечение и профилактика амилоидоза
|
|
CA2711771C
(en)
*
|
2008-01-11 |
2017-01-24 |
Gene Techno Science Co., Ltd. |
Humanized anti-.alpha.9 integrin antibodies and the uses thereof
|
|
MX2010007551A
(es)
|
2008-01-11 |
2010-11-30 |
Synovex Corp |
Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
|
|
EP2243829B1
(en)
|
2008-01-11 |
2014-08-20 |
Astellas Pharma Inc. |
IMPROVED HUMANIZED ANTI-HUMAN alpha9-INTEGRIN ANTIBODY
|
|
PL2246427T3
(pl)
|
2008-02-08 |
2017-06-30 |
Immunas Pharma, Inc. |
Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
|
|
JP5661476B2
(ja)
|
2008-03-04 |
2015-01-28 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
|
|
AU2009224690B2
(en)
|
2008-03-13 |
2014-10-09 |
Biotest Ag |
Agent for treating disease
|
|
JP5795167B2
(ja)
|
2008-03-13 |
2015-10-14 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
|
SG190598A1
(en)
|
2008-03-13 |
2013-06-28 |
Biotest Ag |
Agent for treating disease
|
|
WO2009115531A2
(en)
|
2008-03-17 |
2009-09-24 |
Universitätsklinikum Münster |
Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
|
|
CA2718473A1
(en)
|
2008-03-17 |
2009-09-24 |
Intercell Ag |
Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
|
|
WO2009116670A1
(ja)
|
2008-03-17 |
2009-09-24 |
株式会社リブテック |
in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
|
|
WO2009119794A1
(ja)
|
2008-03-27 |
2009-10-01 |
タカラバイオ株式会社 |
感染症予防、治療剤
|
|
DK2276509T3
(en)
|
2008-04-11 |
2016-09-19 |
Seattle Genetics Inc |
DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
|
WO2009149021A2
(en)
|
2008-06-02 |
2009-12-10 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides
|
|
CA2728473A1
(en)
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
|
CN102164958A
(zh)
|
2008-06-25 |
2011-08-24 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
使用通用抗体构架进行的兔抗体的人源化
|
|
CA2727992C
(en)
|
2008-06-25 |
2017-10-17 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Stable and soluble antibodies inhibiting tnf.alpha.
|
|
CA2728004C
(en)
|
2008-06-25 |
2022-05-24 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Humanization of rabbit antibodies using a universal antibody framework
|
|
SG10201805844QA
(en)
|
2008-07-08 |
2018-08-30 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
ES2613841T3
(es)
|
2008-07-16 |
2017-05-26 |
Medical And Biological Laboratories Co., Ltd. |
Anticuerpo anti-CLCP1 humano y uso del mismo
|
|
CN102170905B
(zh)
|
2008-08-01 |
2016-08-03 |
阿克西斯股份有限公司 |
骨关节炎治疗剂及预防剂
|
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
|
CA2739076A1
(en)
|
2008-10-02 |
2010-04-08 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
|
JP2012505636A
(ja)
|
2008-10-09 |
2012-03-08 |
ミネルバ バイオテクノロジーズ コーポレーション |
細胞において多能性を誘導する方法
|
|
EP3199553B1
(en)
|
2008-10-29 |
2019-04-24 |
Circular Commitment Company |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8940290B2
(en)
|
2008-10-31 |
2015-01-27 |
The Trustees Of The University Of Pennsylvania |
Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
CA2746778C
(en)
|
2008-12-19 |
2019-04-23 |
University Of Zurich |
Human anti-alpha-synuclein autoantibodies
|
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
|
WO2010089340A2
(en)
|
2009-02-05 |
2010-08-12 |
Intercell Ag |
Peptides protective against e. faecalis, methods and uses relating thereto
|
|
WO2010092176A2
(en)
|
2009-02-13 |
2010-08-19 |
Intercell Ag |
Nontypable haemophilus influenzae antigens
|
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
|
ES2584956T3
(es)
|
2009-03-10 |
2016-09-30 |
Baylor Research Institute |
Anticuerpos anti-CD40 y usos de los mismos
|
|
CN105837691B
(zh)
|
2009-03-10 |
2021-06-29 |
贝勒研究院 |
靶向抗原呈递细胞的癌症疫苗
|
|
DK2406288T3
(en)
|
2009-03-10 |
2017-03-27 |
Baylor Res Inst |
ANTIGEN PRESENTING CELL-TARGETED VACCINES
|
|
WO2010109924A1
(ja)
|
2009-03-25 |
2010-09-30 |
国立大学法人東北大学 |
Ｌｈ型二重特異性抗体
|
|
MX2011007342A
(es)
|
2009-04-09 |
2011-07-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
|
|
EP2990051B1
(en)
|
2009-04-10 |
2016-10-26 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
|
WO2010119704A1
(en)
|
2009-04-17 |
2010-10-21 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
|
EP2424594A4
(en)
|
2009-04-29 |
2014-12-24 |
Abbvie Biotechnology Ltd |
AUTOMATIC INJECTION DEVICE
|
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
|
EP2270053A1
(en)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanized AXL antibodies
|
|
CN102575232B
(zh)
|
2009-05-29 |
2015-07-22 |
宾夕法尼亚大学托管会 |
猿腺病毒41及其应用
|
|
EP2260864A1
(en)
|
2009-06-10 |
2010-12-15 |
University of Melbourne |
Therapeutic applications
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
US10087252B2
(en)
|
2009-07-24 |
2018-10-02 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with αvβ5 integrin
|
|
EP2459053A2
(en)
|
2009-07-28 |
2012-06-06 |
F. Hoffmann-La Roche AG |
Non-invasive in vivo optical imaging method
|
|
EP2462451B1
(en)
|
2009-08-05 |
2016-02-17 |
Nexigen GmbH |
Human hcv-interacting proteins and methods of use
|
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗ｃｄｃｐ１抗體
|
|
IN2012DN02764A
(no)
|
2009-08-31 |
2015-09-18 |
Amplimmune Inc |
|
|
AU2010291985B2
(en)
|
2009-09-14 |
2016-05-05 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
EP2308897A1
(en)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
|
|
ES2666372T3
(es)
|
2009-10-11 |
2018-05-04 |
Biogen Ma Inc. |
Ensayos relacionados con anti-VLA-4
|
|
JP5818003B2
(ja)
|
2009-11-18 |
2015-11-18 |
国立大学法人東北大学 |
ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
|
|
EP2332929A1
(en)
|
2009-11-25 |
2011-06-15 |
ArisGen SA |
Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
|
WO2011075578A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
WO2011088193A2
(en)
|
2010-01-13 |
2011-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
|
|
AU2011207253B2
(en)
|
2010-01-20 |
2015-02-12 |
Merck Sharp & Dohme Corp. |
Anti-ILT5 antibodies and ILT5-binding antibody fragments
|
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
BR112012018825A2
(pt)
|
2010-01-29 |
2019-09-24 |
Axis Inc |
composição farmacêutica para tratamento ou prevenção da osteoartrite e método para fabricação da mesma.
|
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
|
CN102821786B
(zh)
|
2010-01-29 |
2016-01-13 |
阿克西斯股份有限公司 |
含有骨关节炎治疗剂的注射液
|
|
EP2531613A2
(en)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
|
UA115517C2
(uk)
|
2010-02-08 |
2017-11-27 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
|
|
BR112012020790B1
(pt)
|
2010-02-18 |
2021-09-28 |
The Regents Of The University Of California |
Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
|
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
|
US9216217B2
(en)
*
|
2010-03-03 |
2015-12-22 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
|
WO2011117392A2
(en)
|
2010-03-26 |
2011-09-29 |
Universitaetsklinikum Muenster |
Substitute therapy for glucocorticoids
|
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
|
HUE027760T2
(en)
|
2010-04-09 |
2016-11-28 |
Critical Care Diagnostics Inc |
Soluble human ST-2 antibodies and assays
|
|
EP4032912B1
(en)
|
2010-04-16 |
2025-05-28 |
Biogen MA Inc. |
Anti-vla-4 antibodies
|
|
SG10201503130UA
(en)
|
2010-04-21 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Wearable automatic injection device for controlled delivery of therapeutic agents
|
|
JP6145404B2
(ja)
|
2010-05-07 |
2017-06-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エクスビボでの細胞の検出のための診断的方法
|
|
MX350781B
(es)
|
2010-05-17 |
2017-09-18 |
Livtech Inc * |
Anticuerpo anti-humano trop-2 que tiene actividad anti-tumoral in vivo.
|
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
|
JP5934203B2
(ja)
|
2010-07-14 |
2016-06-15 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗ａｄｄｌモノクローナル抗体およびこの使用
|
|
BR112013001062A2
(pt)
|
2010-07-15 |
2016-05-24 |
Synovex Corp |
anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
|
|
PL2598526T4
(pl)
|
2010-07-29 |
2019-05-31 |
Eleven Biotherapeutics Inc |
Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
|
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
|
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
|
US9034333B2
(en)
|
2010-08-27 |
2015-05-19 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
|
US20130156785A1
(en)
|
2010-08-27 |
2013-06-20 |
University Of Zurich |
Novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
|
TR201812636T4
(tr)
|
2010-10-11 |
2018-09-21 |
Biogen Int Neuroscience Gmbh |
İnsan anti-tau antikorları.
|
|
MX392780B
(es)
|
2010-10-13 |
2025-03-24 |
Janssen Biotech Inc |
Polinucléotidos que condifican anticuerpos de oncostatina m humana
|
|
AU2011317743B2
(en)
|
2010-10-18 |
2015-05-21 |
Mediapharma S.R.L. |
ErbB3 binding antibody
|
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
|
WO2012054748A2
(en)
|
2010-10-22 |
2012-04-26 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
EP3326645B1
(en)
|
2010-10-25 |
2020-03-18 |
Biogen MA Inc. |
Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
|
|
AU2011322508A1
(en)
|
2010-10-27 |
2013-05-02 |
Pierre Fabre Medicament |
Antibodies for the treatment of HIV
|
|
RU2644678C1
(ru)
|
2010-10-29 |
2018-02-13 |
Дайити Санкио Компани, Лимитед |
Новое антитело против dr5
|
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
|
CA2818548A1
(en)
|
2010-11-19 |
2012-05-24 |
Toshio Imai |
Neutralizing anti-ccl20 antibodies
|
|
EP2643465B1
(en)
|
2010-11-23 |
2016-05-11 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenovirus a1321 and uses thereof
|
|
US9283271B2
(en)
|
2010-12-17 |
2016-03-15 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
|
WO2012090939A1
(ja)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
|
|
DK2663580T3
(en)
|
2011-01-10 |
2017-03-13 |
Ct Atlantic Ltd |
COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
|
|
CA3027071A1
(en)
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
RU2727040C2
(ru)
|
2011-01-24 |
2020-07-17 |
Эббви Байотекнолоджи Лтд. |
Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
|
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
|
WO2012113775A1
(en)
|
2011-02-21 |
2012-08-30 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
|
EP2683290B1
(en)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Methods for in vivo testing of therapeutic antibodies
|
|
EP2683413A1
(en)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
|
EP2686417B1
(de)
|
2011-03-17 |
2016-06-08 |
Miltenyi Biotec GmbH |
Tcralpha/beta-depletierte zellpräparationen
|
|
CA2830503A1
(en)
|
2011-03-17 |
2012-09-20 |
Minerva Biotechnologies Corporation |
Method for making pluripotent stem cells
|
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
CN103619378B
(zh)
|
2011-04-21 |
2017-03-01 |
艾伯维公司 |
可佩戴式自动注射装置
|
|
AU2012248470B2
(en)
|
2011-04-25 |
2016-10-27 |
Daiichi Sankyo Company, Limited |
Anti-B7-H3 antibody
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
LT2704742T
(lt)
|
2011-05-02 |
2017-10-25 |
Millennium Pharmaceuticals, Inc. |
Anti-alfa4beta7 antikūno kompozicija
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
US20140086827A1
(en)
|
2011-05-09 |
2014-03-27 |
The Cleveland Clinic Foundation |
Serum S100B And Uses Thereof
|
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
|
EP2714742A1
(en)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Magea3 binding antibodies
|
|
US20140186363A1
(en)
|
2011-06-03 |
2014-07-03 |
University Of Zurich |
Magea3 binding antibodies
|
|
HK1197072A1
(en)
|
2011-06-06 |
2015-01-02 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
|
US20140308275A1
(en)
|
2011-07-27 |
2014-10-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Methods for diagnosing and treating myhre syndrome
|
|
KR101999867B1
(ko)
|
2011-08-11 |
2019-07-12 |
아스텔라스세이야쿠 가부시키가이샤 |
신규 항 인간 ngf 항체
|
|
EP2743699A4
(en)
|
2011-08-12 |
2015-04-08 |
Nat Inst Infectious Diseases |
METHOD FOR TESTING, PREVENTING AND TREATING INFECTIOUS DISEASE ASPERGILLUS FUMIGATUS AND COMPOSITION
|
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
BR112014006376B1
(pt)
|
2011-09-19 |
2021-07-27 |
Axon Neuroscience Se |
Anticorpo isolado que se liga a um ou mais epítopos tau, ácido nucleico, vetor, composição farmacêutica, artigo de fabricação, dispositivo médico, método in vitro para diagnosticar ou triar um indivíduo quanto à presença de doença de alzheimer ou de uma tauopatia relacionada e usos do referido anticorpo
|
|
GB2495115A
(en)
*
|
2011-09-29 |
2013-04-03 |
Oxford Plastic Sys Ltd |
Base for supporting temporary fence panels or posts.
|
|
TW201329105A
(zh)
|
2011-10-04 |
2013-07-16 |
Thr Trustees Of Columbia University In The City Of New York |
人類ｎｏｔｃｈ１引誘物
|
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
|
US20140248294A1
(en)
|
2011-10-05 |
2014-09-04 |
University Of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
|
CA2852244C
(en)
|
2011-10-17 |
2023-10-17 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
|
US20140248284A1
(en)
|
2011-10-20 |
2014-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the detection and the treatment of cardiac remodeling
|
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
|
CN103998466A
(zh)
|
2011-11-22 |
2014-08-20 |
国家医疗保健研究所 |
用于降低气道高反应的方法和药物组合物
|
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
|
WO2013079487A1
(en)
|
2011-11-28 |
2013-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of dysfunction associated with aging
|
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
|
RU2658438C2
(ru)
*
|
2011-12-13 |
2018-06-21 |
Нордик Нановектор Аса |
Химерное терапевтическое антитело нн1 против cd-37
|
|
US20150030602A1
(en)
|
2011-12-23 |
2015-01-29 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
|
AU2013206788B2
(en)
|
2011-12-28 |
2017-11-30 |
Immunoqure Ag |
Method of providing monoclonal auto-antibodies with desired specificity
|
|
JP2015509085A
(ja)
|
2012-01-01 |
2015-03-26 |
キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． |
治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
|
|
EP2812702B1
(en)
|
2012-02-10 |
2019-04-17 |
Seattle Genetics, Inc. |
Diagnosis and management of CD30-expressing cancers
|
|
AU2013221635B2
(en)
|
2012-02-16 |
2017-12-07 |
Santarus, Inc. |
Anti-VLA1 (CD49a) antibody pharmaceutical compositions
|
|
EP2817340B1
(en)
|
2012-02-23 |
2020-12-09 |
Daiichi Sankyo Europe GmbH |
Her3 inhibitor for modulating radiosensitivity
|
|
WO2013129454A1
(ja)
|
2012-02-28 |
2013-09-06 |
アステラス製薬株式会社 |
新規抗ヒトｉｌ－２３受容体抗体
|
|
MY175224A
(en)
|
2012-03-15 |
2020-06-16 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods, and uses
|
|
HUE044838T2
(hu)
|
2012-03-20 |
2019-11-28 |
Biogen Ma Inc |
JCV neutralizáló antitestek
|
|
KR20140138215A
(ko)
|
2012-03-30 |
2014-12-03 |
다이이찌 산쿄 가부시키가이샤 |
신규 항 Ｓｉｇｌｅｃ-15 항체
|
|
NZ631509A
(en)
|
2012-03-30 |
2016-09-30 |
Daiichi Sankyo Co Ltd |
Cdr-modified anti-siglec-15 antibody
|
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
CA2869394A1
(en)
|
2012-04-02 |
2013-10-10 |
Gundersen Lutheran Health System, Inc. |
Reagents, methods, and kits for the classification of cancer
|
|
SG11201406422TA
(en)
|
2012-04-09 |
2014-11-27 |
Daiichi Sankyo Co Ltd |
Anti-fgfr2 antibody
|
|
MY166821A
(en)
|
2012-04-27 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
Anti-robo4-antibody
|
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
|
WO2013172951A1
(en)
|
2012-05-15 |
2013-11-21 |
Morphotek, Inc. |
Methods for treatment of gastric cancer
|
|
KR20150014505A
(ko)
|
2012-05-18 |
2015-02-06 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
아과 e 원숭이 아데노바이러스 a1302, a1320, a1331 및 a1337 및 이것들의 사용
|
|
JP2015520373A
(ja)
|
2012-05-22 |
2015-07-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
巣状分節性糸球体硬化症を診断及び処置するための方法
|
|
MX369626B
(es)
|
2012-05-24 |
2019-11-13 |
Mountgate Group Ltd |
Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
|
|
KR102204029B1
(ko)
|
2012-07-13 |
2021-01-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ｃａｒ의 항-종양 활성에 대한 독성 관리
|
|
EP2875049B1
(en)
|
2012-07-18 |
2018-12-26 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for preventing and treating chronic kidney disease (ckd)
|
|
EP3539563A1
(en)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
AU2013297478B2
(en)
|
2012-07-30 |
2018-12-20 |
Medical & Biological Laboratories Co., Ltd. |
Monoclonal antibody against human midkine
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
TW201922795A
(zh)
|
2012-09-10 |
2019-06-16 |
愛爾蘭商尼歐托普生物科學公司 |
抗ｍｃａｍ抗體及相關使用方法
|
|
WO2014042251A1
(ja)
|
2012-09-13 |
2014-03-20 |
中外製薬株式会社 |
遺伝子ノックイン非ヒト動物
|
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
|
EP2905335B1
(en)
|
2012-10-03 |
2018-01-31 |
Chiome Bioscience Inc. |
Anti-human dlk-1 antibody having anti-tumor activity in vivo
|
|
US9540439B2
(en)
|
2012-10-08 |
2017-01-10 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
|
|
MX364484B
(es)
|
2012-10-11 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo-fármaco.
|
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
|
ES2782248T3
(es)
|
2012-10-19 |
2020-09-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
|
|
US20150246118A1
(en)
|
2012-10-26 |
2015-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
|
CA2889764C
(en)
|
2012-11-01 |
2023-10-10 |
Martin Lipp |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
BR112015010046B1
(pt)
|
2012-11-05 |
2023-05-02 |
Pierre Fabre Medicament |
Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino
|
|
JP6445446B2
(ja)
|
2012-11-08 |
2018-12-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨転移の治療のための方法及び医薬組成物
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
MX363407B
(es)
|
2012-12-10 |
2019-03-22 |
Biogen Ma Inc |
Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
|
|
WO2014096672A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
|
CA2896066C
(en)
|
2012-12-21 |
2022-07-12 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
|
CN104936980B
(zh)
|
2012-12-31 |
2019-06-07 |
生物控股有限公司 |
用于治疗和预防多瘤病毒相关的疾病的重组人抗体
|
|
EP2752426A1
(en)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Human serum albumin binding compounds and fusion proteins thereof
|
|
SI2949675T1
(sl)
|
2013-01-28 |
2021-08-31 |
Evec Inc. |
Humanizirano protitelo ANTI-HMGB1 ali njegov antigen-vezavni fragment
|
|
JP2016508606A
(ja)
|
2013-02-01 |
2016-03-22 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法
|
|
WO2014123227A1
(ja)
|
2013-02-08 |
2014-08-14 |
株式会社医学生物学研究所 |
ヒトｎｒｇ１タンパク質に対する抗体
|
|
WO2014124677A1
(en)
|
2013-02-15 |
2014-08-21 |
Esbatech - A Novartis Company Llc |
Acceptor framework for cdr grafting
|
|
CN104884471A
(zh)
|
2013-02-20 |
2015-09-02 |
艾斯巴技术-诺华有限责任公司 |
用于cdr移植的受体框架
|
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
|
JP6490574B2
(ja)
|
2013-02-28 |
2019-03-27 |
国立研究開発法人国立がん研究センター |
不溶性フィブリンに対する抗体
|
|
WO2014136910A1
(ja)
|
2013-03-08 |
2014-09-12 |
国立大学法人大阪大学 |
ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
|
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
|
CN107693781B
(zh)
|
2013-03-13 |
2021-11-09 |
巴扎德制药公司 |
用于眼部递送的嵌合细胞因子制剂
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US10081673B2
(en)
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
|
CN105392801A
(zh)
|
2013-03-15 |
2016-03-09 |
比奥根Ma公司 |
使用抗αvβ5抗体治疗和预防急性肾损伤
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
WO2014165524A2
(en)
|
2013-04-01 |
2014-10-09 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with avb8 integrin
|
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
EP3159695A3
(en)
|
2013-06-20 |
2017-07-05 |
The Trustees of The University of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
|
US10112995B2
(en)
|
2013-07-03 |
2018-10-30 |
Immunoqure Ag |
Human anti-IFN-α antibodies
|
|
JP6450381B2
(ja)
|
2013-07-05 |
2019-01-09 |
ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション |
がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
|
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
AR097293A1
(es)
|
2013-08-09 |
2016-03-02 |
Astellas Pharma Inc |
Anticuerpo contra el receptor de tslp humana
|
|
US20160216262A1
(en)
|
2013-09-12 |
2016-07-28 |
Institut National De La Sante Et De La Recherche Medicale |
Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
|
|
AU2014322988B2
(en)
|
2013-09-20 |
2018-12-06 |
Westfaelische Wilhelms-Universitaet Muenster |
Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
|
|
EP3049438B1
(en)
|
2013-09-24 |
2018-07-25 |
The Feinstein Institute for Medical Research |
Peptides inhibiting cold-inducible rna binding protein activity
|
|
US9974788B2
(en)
|
2013-09-26 |
2018-05-22 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of SGK1 in the treatment of heart conditions
|
|
SG11201602490UA
(en)
|
2013-09-30 |
2016-04-28 |
Daiichi Sankyo Co Ltd |
Anti-lps o11 antibody
|
|
EP3052131B1
(en)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
ES2768618T3
(es)
|
2013-10-08 |
2020-06-23 |
Daiichi Sankyo Co Ltd |
Combinación de anticuerpo anti-FGFR2 y otro agente
|
|
PL3065774T3
(pl)
|
2013-11-06 |
2021-12-13 |
Janssen Biotech, Inc |
Przeciwciała anty-ccl17
|
|
WO2015068781A1
(ja)
|
2013-11-06 |
2015-05-14 |
国立大学法人大阪大学 |
インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
|
|
EP3068419A1
(en)
|
2013-11-15 |
2016-09-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of pancreatic cancers
|
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
|
CN109535254B
(zh)
|
2013-12-24 |
2022-06-24 |
安斯泰来制药株式会社 |
抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
|
|
HRP20250673T1
(hr)
|
2013-12-25 |
2025-08-01 |
Daiichi Sankyo Company, Limited |
Postupak za proizvodnju konjugata anti-trop2 antitijelo-lijek
|
|
EP4101461A1
(en)
|
2014-01-09 |
2022-12-14 |
Hadasit Medical Research Services and Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
|
CN120939216A
(zh)
|
2014-01-13 |
2025-11-14 |
贝勒研究院 |
抗hpv和hpv相关的疾病的新疫苗
|
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
|
KR102314913B1
(ko)
|
2014-01-31 |
2021-10-19 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
|
ES2831014T3
(es)
|
2014-02-18 |
2021-06-07 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR
|
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
|
EP3415160B1
(en)
|
2014-03-04 |
2021-08-18 |
Klinikum der Universität München |
Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
|
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
|
EP3122768A2
(en)
|
2014-03-27 |
2017-02-01 |
Yeda Research and Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
|
KR102186027B1
(ko)
|
2014-04-10 |
2020-12-03 |
다이이치 산쿄 유럽 게엠베하 |
항her3 항체-약물 콘주게이트
|
|
CA2940585C
(en)
|
2014-04-15 |
2023-08-08 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Differential diagnosis of eczema and psoriasis
|
|
CA2944903A1
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
|
BR112016024363A2
(pt)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
|
|
HUE052223T2
(hu)
|
2014-04-25 |
2021-04-28 |
Pf Medicament |
IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
|
|
US10633448B2
(en)
|
2014-04-25 |
2020-04-28 |
Pierre Fabre Medicament |
IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
PE20170764A1
(es)
|
2014-04-27 |
2017-07-04 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1)
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
WO2015200790A2
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
|
WO2016011383A1
(en)
|
2014-07-17 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
|
CN120518772A
(zh)
|
2014-07-17 |
2025-08-22 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
EP3174898A2
(en)
|
2014-07-29 |
2017-06-07 |
Neurimmune Holding AG |
Human-derived anti-huntingtin (htt) antibodies and uses thereof
|
|
CN108064248B
(zh)
|
2014-09-30 |
2022-03-15 |
生物控股有限公司 |
人源抗二肽重复(dpr)抗体
|
|
SG11201702606TA
(en)
|
2014-10-03 |
2017-04-27 |
Massachusetts Inst Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
JP6941561B2
(ja)
|
2014-10-09 |
2021-09-29 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
|
|
US11033637B2
(en)
|
2014-11-21 |
2021-06-15 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
|
US20180031579A1
(en)
|
2015-02-12 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
|
HK1248812A1
(zh)
|
2015-03-06 |
2018-10-19 |
Dana-Farber Cancer Institute, Inc. |
预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
JP2018516230A
(ja)
|
2015-03-18 |
2018-06-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
カリウムチャネルｋｃｎｋ９を標的とする新規モノクローナル抗体阻害剤
|
|
WO2016151018A1
(en)
|
2015-03-24 |
2016-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
US10214591B1
(en)
|
2015-04-03 |
2019-02-26 |
Alienor Farma |
Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
|
EP3283108B1
(en)
|
2015-04-13 |
2020-10-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
|
|
JP2018519248A
(ja)
|
2015-04-22 |
2018-07-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔｈ１７媒介性疾患の処置のための方法及び医薬組成物
|
|
KR20180020202A
(ko)
|
2015-06-01 |
2018-02-27 |
메디진 이뮤노테라피스 게엠바하 |
T 세포 수용체 특이적 항체
|
|
AU2016273214B2
(en)
|
2015-06-01 |
2018-10-18 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against T cell receptor
|
|
EP3303591B1
(en)
|
2015-06-01 |
2019-04-03 |
Medigene Immunotherapies GmbH |
T cell receptor library
|
|
PT3310800T
(pt)
|
2015-06-19 |
2022-03-21 |
Centurion Biopharma Corp |
Sistemas de administração para a libertação controlada de fármacos
|
|
JP2018524588A
(ja)
|
2015-06-26 |
2018-08-30 |
ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド |
骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
|
|
AU2016286898B2
(en)
|
2015-06-29 |
2022-12-08 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
US10669343B2
(en)
|
2015-08-05 |
2020-06-02 |
Janssen Biotech, Inc. |
Anti-CD154 antibodies and methods of using them
|
|
AU2016319133B2
(en)
|
2015-09-11 |
2023-06-08 |
Mark C. Glassy |
Enhanced delivery of drugs to the brain
|
|
EP3350212A1
(en)
|
2015-09-18 |
2018-07-25 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
|
DK3353196T5
(da)
|
2015-09-22 |
2024-09-30 |
Inst Nat Sante Rech Med |
Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
|
|
AU2016325858B2
(en)
|
2015-09-24 |
2022-05-26 |
Daiichi Sankyo Company, Limited |
Anti-GARP antibody
|
|
CN108368510B
(zh)
|
2015-09-30 |
2023-09-01 |
詹森生物科技公司 |
特异性结合人cd40的激动性抗体和使用方法
|
|
CN108138171B
(zh)
|
2015-10-08 |
2022-05-13 |
国立大学法人名古屋大学 |
表达嵌合抗原受体的基因修饰t细胞的制备方法
|
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
|
WO2017064302A1
(en)
|
2015-10-16 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
AU2016344663B2
(en)
|
2015-10-26 |
2023-09-07 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
|
MY198562A
(en)
|
2015-11-03 |
2023-09-05 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
EP3901254A1
(en)
|
2015-12-23 |
2021-10-27 |
Medigene Immunotherapies GmbH |
Novel generation of antigen-specific tcrs
|
|
BR112018013272A2
(pt)
|
2015-12-31 |
2018-12-11 |
Progastrine Et Cancers S A R L |
composições e métodos para detectar e tratar câncer esofágico
|
|
ES3015244T3
(en)
|
2015-12-31 |
2025-04-30 |
Ecs Progastrin Sa |
Compositions and methods for detecting and treating ovarian cancer
|
|
KR102477179B1
(ko)
|
2015-12-31 |
2022-12-13 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
위암의 검출 및 치료를 위한 조성물 및 방법
|
|
EP3202788A1
(en)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialin-binding antibody
|
|
EP3416688B1
(en)
|
2016-02-15 |
2022-08-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Apelin for use in the treatment of post-operative cognitive dysfunction
|
|
EP3205663A1
(en)
|
2016-02-15 |
2017-08-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for inhibiting gene expression
|
|
EP4043492A1
(en)
|
2016-03-01 |
2022-08-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Antibodies specific to human poliovirus receptor (pvr)
|
|
WO2017153432A1
(en)
|
2016-03-07 |
2017-09-14 |
Pierre Fabre Medicament |
A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
|
ES2944259T3
(es)
|
2016-03-15 |
2023-06-20 |
Inst Nat Sante Rech Med |
Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer
|
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
|
WO2017162604A1
(en)
|
2016-03-21 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and treatment of solar lentigo
|
|
RU2744959C2
(ru)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
Новые анти-pd-l1 антитела
|
|
EP3436461B1
(en)
|
2016-03-28 |
2023-11-01 |
Incyte Corporation |
Pyrrolotriazine compounds as tam inhibitors
|
|
ITUA20162242A1
(it)
|
2016-04-01 |
2017-10-01 |
St Biochimico Italiano Giovanni Lorenzini Spa |
Un nuovo anticorpo anti-erbb2
|
|
HRP20221149T1
(hr)
|
2016-04-18 |
2022-11-25 |
Faron Pharmaceuticals Oy |
Humanizirana antitijela protiv clever-1 i njihova primjena
|
|
US11406686B2
(en)
|
2016-05-03 |
2022-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of tissue lesions with CCR2 agonists
|
|
KR102323519B1
(ko)
|
2016-05-11 |
2021-11-09 |
암젠 인크 |
글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택
|
|
US20190290756A1
(en)
|
2016-05-20 |
2019-09-26 |
Christoph Karl |
Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d
|
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
|
EP3464357A1
(en)
|
2016-05-24 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
|
KR102497013B1
(ko)
|
2016-06-07 |
2023-02-20 |
맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 |
Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
JP2019522800A
(ja)
|
2016-07-06 |
2019-08-15 |
プロセナ バイオサイエンシーズ リミテッド |
総及びＳ１２９リン酸化α−シヌクレインの検出アッセイ
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
|
EP3491387A1
(en)
|
2016-07-28 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
JP7466308B2
(ja)
|
2016-09-20 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
|
|
SG10201912173RA
(en)
|
2016-10-07 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
CR20210094A
(es)
|
2016-10-13 |
2021-03-31 |
Massachusetts Inst Technology |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
|
|
IT201600111877A1
(it)
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
|
JOP20190103B1
(ar)
|
2016-11-18 |
2023-09-17 |
Astellas Pharma Inc |
شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
|
|
KR20250040100A
(ko)
|
2016-12-12 |
2025-03-21 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
|
|
CA3046432A1
(en)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
EP3555128B1
(en)
|
2016-12-15 |
2023-12-27 |
The National Institute for Biotechnology in the Negev Ltd. |
Anti-pcna monoclonal antibodies and use thereof
|
|
FI3561057T3
(fi)
|
2016-12-22 |
2025-10-07 |
Daiichi Sankyo Co Ltd |
Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
|
|
US20180179490A1
(en)
|
2016-12-27 |
2018-06-28 |
Miltenyi Biotec Gmbh |
CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
|
|
WO2018129284A1
(en)
|
2017-01-05 |
2018-07-12 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
|
|
CA3050668C
(en)
|
2017-01-17 |
2023-08-15 |
Daiichi Sankyo Company, Limited |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
|
JPWO2018147245A1
(ja)
|
2017-02-07 |
2019-11-21 |
第一三共株式会社 |
抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
|
|
EP3363459A1
(en)
|
2017-02-17 |
2018-08-22 |
Alexander Klimka |
Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
|
|
CA3092434A1
(en)
|
2017-02-27 |
2018-08-30 |
Caerus Therapeutics, Inc. |
Compositions of a novel anti-human ceacam6 antibody and uses thereof
|
|
CN117982673A
(zh)
|
2017-02-28 |
2024-05-07 |
第一三共株式会社 |
抗her3抗体-药物偶联物的应用
|
|
EP4095161A1
(en)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Novel anti-trkb antibodies
|
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
|
US11614448B2
(en)
|
2017-03-30 |
2023-03-28 |
Ecs-Progastrin Sa |
Compositions and methods for detecting prostate cancer
|
|
ES2926532T3
(es)
|
2017-03-30 |
2022-10-26 |
Progastrine Et Cancers S A R L |
Composiciones y métodos para tratar el cáncer de pulmón
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
WO2018189335A1
(en)
|
2017-04-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
CN111201034A
(zh)
|
2017-05-11 |
2020-05-26 |
西托戴恩股份有限公司 |
涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
|
|
TW202532106A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物之製造方法
|
|
KR102692379B1
(ko)
|
2017-06-05 |
2024-08-05 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 사용 방법
|
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
|
AU2018286932A1
(en)
|
2017-06-23 |
2020-01-16 |
Mabylon Ag |
Anti-allergen antibodies
|
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
|
CN110913905A
(zh)
|
2017-06-30 |
2020-03-24 |
国立大学法人北海道大学 |
不产生生长障碍的小儿骨质疏松症治疗药
|
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
BR112020001255A2
(pt)
|
2017-07-21 |
2020-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
composições imunogênicas de neisseria meningitidis
|
|
BR112020001657A2
(pt)
|
2017-07-27 |
2020-07-21 |
Daiichi Sankyo Company, Limited |
Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico
|
|
WO2019020734A1
(en)
|
2017-07-28 |
2019-01-31 |
Biouniversa S.R.L. |
ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
|
|
EP3625254B1
(en)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Three-dimensional structure-based humanization method
|
|
EP3444272A1
(en)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Treatment of ck8 positive cancers in relation with k-ras gene status
|
|
KR102804751B1
(ko)
|
2017-08-23 |
2025-05-13 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
|
|
TWI880888B
(zh)
|
2017-08-23 |
2025-04-21 |
日商第一三共股份有限公司 |
抗體－藥物結合物之製劑及其冷凍乾燥方法
|
|
JP7248578B2
(ja)
|
2017-08-31 |
2023-03-29 |
第一三共株式会社 |
抗体－薬物コンジュゲートの新規製造方法
|
|
KR102816741B1
(ko)
|
2017-08-31 |
2025-06-04 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
MY208007A
(en)
|
2017-09-27 |
2025-04-04 |
Incyte Corp |
Salts of pyrrolotriazine derivatives useful as tam inhibitors
|
|
AU2018342527B2
(en)
|
2017-09-29 |
2024-06-27 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US20200345800A1
(en)
|
2017-10-03 |
2020-11-05 |
Tokyo Metropolitan Institute Of Medical Science |
Medication for influenza
|
|
TW201927336A
(zh)
|
2017-10-05 |
2019-07-16 |
日商第一三共股份有限公司 |
細胞毒性ｔ細胞耗竭用組成物
|
|
KR101966362B1
(ko)
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
US11591385B2
(en)
|
2017-11-09 |
2023-02-28 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
|
IL305268A
(en)
|
2017-11-30 |
2023-10-01 |
Centurion Biopharma Corp |
Maytansinoid-based drug delivery systems
|
|
US11377473B2
(en)
|
2017-11-30 |
2022-07-05 |
Centurion Biopharma Corporation |
Albumin-binding prodrugs of auristatin E derivatives
|
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
|
JP7104153B2
(ja)
|
2017-12-05 |
2022-07-20 |
プロガストリン、エ、カンセル、エス、アー エル、エル |
癌を治療するための抗プロガストリン抗体と免疫療法の併用療法
|
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ｅｃｓ前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
|
WO2019155474A1
(en)
|
2018-02-12 |
2019-08-15 |
Hadasit Medical Research Services & Development Ltd. |
Modulation of slamf6 splice variants for cancer therapy
|
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
|
US20200400675A1
(en)
|
2018-02-27 |
2020-12-24 |
Ecs-Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
|
CA3090305A1
(en)
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
BR112020017451A2
(pt)
|
2018-03-05 |
2020-12-22 |
Saitama Medical University |
Composição farmacêutica para tratamento ou prevenção de ossificação heterotópica
|
|
EA202092088A1
(ru)
|
2018-03-05 |
2020-11-13 |
Янссен Фармацевтика Нв |
Антитела анти-phf-тау и их применение
|
|
US12186343B2
(en)
|
2018-03-09 |
2025-01-07 |
Crage Medical Co., Limited |
Method and composition for treating tumors
|
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
US12103972B2
(en)
|
2018-04-06 |
2024-10-01 |
Dana-Farber Cancer Institute, Inc. |
KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
|
|
JP2021521445A
(ja)
|
2018-04-13 |
2021-08-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
|
|
CN112189018A
(zh)
|
2018-04-20 |
2021-01-05 |
汉诺威医学院 |
结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
|
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
KR102892725B1
(ko)
|
2018-05-09 |
2025-12-01 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴4에 특이적인 항체
|
|
EP3795688A4
(en)
|
2018-05-11 |
2022-01-19 |
Astellas Pharma Inc. |
Nucleic acid for treating mite allergy
|
|
MX2020012055A
(es)
|
2018-05-11 |
2021-01-29 |
Astellas Pharma Inc |
Acido nucleico para el tratamiento de alergia por crustaceos.
|
|
WO2019221269A1
(ja)
|
2018-05-17 |
2019-11-21 |
アステラス製薬株式会社 |
抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
|
JP2021524255A
(ja)
|
2018-05-24 |
2021-09-13 |
ヤンセン バイオテツク，インコーポレーテツド |
単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
|
|
SMT202500221T1
(it)
|
2018-05-24 |
2025-07-22 |
Janssen Biotech Inc |
Anticorpi anti-cd3 e usi di essi
|
|
CN120501882A
(zh)
|
2018-05-28 |
2025-08-19 |
第一三共株式会社 |
通过施用抗her2抗体-药物缀合物治疗her2突变的癌
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
MY208015A
(en)
|
2018-05-31 |
2025-04-07 |
Univ Tokyo |
Anti-human tlr7 antibody
|
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Ｂｃｍａに対する結合分子及びその使用
|
|
CN119080931A
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
EP4349411A3
(en)
|
2018-06-20 |
2024-06-19 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
|
US12129298B2
(en)
|
2018-06-21 |
2024-10-29 |
Daiichi Sankyo Company, Limited |
Compositions including CD3 antigen binding fragments and uses thereof
|
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
US20210283269A1
(en)
|
2018-07-25 |
2021-09-16 |
Daiichi Sankyo Company, Limited |
Effective method for manufacturing antibody-drug conjugate
|
|
EP3831408A4
(en)
|
2018-07-27 |
2021-11-17 |
Osaka University |
COMPOSITION TO INHIBIT AGING, PREVENT, IMPROVE, OR TREAT AGE-RELATED DISEASES, OR EXTEND LIFE
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
CN112805036A
(zh)
|
2018-07-31 |
2021-05-14 |
第一三共株式会社 |
通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
|
|
CN112512587A
(zh)
|
2018-08-06 |
2021-03-16 |
第一三共株式会社 |
抗体药物缀合物和微管蛋白抑制剂的组合
|
|
MX2021002107A
(es)
|
2018-09-06 |
2021-04-28 |
Daiichi Sankyo Co Ltd |
Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo.
|
|
TW202024133A
(zh)
|
2018-09-20 |
2020-07-01 |
日商第一三共股份有限公司 |
利用投予抗her3抗體-藥物結合物之her3突變癌之治療
|
|
JP7475687B2
(ja)
|
2018-09-21 |
2024-04-30 |
国立大学法人 東京医科歯科大学 |
ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
|
US12011485B2
(en)
|
2018-09-27 |
2024-06-18 |
Pierre Fabre Medicament |
Sulfomaleimide-based linkers and corresponding conjugates
|
|
US20220048966A1
(en)
|
2018-09-28 |
2022-02-17 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
|
CN117752825A
(zh)
|
2018-10-10 |
2024-03-26 |
安斯泰来制药株式会社 |
含有标记部-抗人抗体Fab片段复合物的药物组合物
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20210340240A1
(en)
|
2018-10-18 |
2021-11-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
JP7415939B2
(ja)
|
2018-10-31 |
2024-01-17 |
アステラス製薬株式会社 |
抗ヒトＦｎ１４抗体
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020099235A1
(en)
|
2018-11-12 |
2020-05-22 |
Mediapharma S.R.L. |
Bispecific antibodies directed against human 90k and either endosialin or her3
|
|
BR112021009251A2
(pt)
|
2018-11-14 |
2021-08-10 |
Daiichi Sankyo Company, Limited |
conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
|
|
US12227548B2
(en)
|
2018-11-19 |
2025-02-18 |
Dana-Farber Cancer Institute, Inc. |
Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
|
|
SG11202106248XA
(en)
|
2018-12-11 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate with parp inhibitor
|
|
EP3897854A2
(en)
|
2018-12-21 |
2021-10-27 |
Aim Immunotech Inc. |
Compositions and methods for cancer therapy
|
|
CN113195000A
(zh)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
抗体-药物缀合物和激酶抑制剂的组合
|
|
JOP20210183A1
(ar)
|
2019-01-07 |
2023-01-30 |
Astellas Pharma Inc |
مادة اقتران تشتمل على ربيطة وشدفة Fab لجسم مضاد لـ CEACAM5
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
KR20210117277A
(ko)
|
2019-01-13 |
2021-09-28 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴-2에 특이적인 항체
|
|
WO2020157122A1
(en)
|
2019-01-29 |
2020-08-06 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
KR20210126078A
(ko)
|
2019-02-13 |
2021-10-19 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
항-말초 림프절 어드레신 항체 및 그의 용도
|
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
|
KR20210152472A
(ko)
|
2019-03-11 |
2021-12-15 |
메모리얼 슬로안 케터링 캔서 센터 |
Cd22 항체 및 이를 사용하는 방법
|
|
US20220154153A1
(en)
|
2019-03-22 |
2022-05-19 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
|
CN113631229B
(zh)
|
2019-03-25 |
2025-09-23 |
第一三共株式会社 |
抗体－吡咯并苯并二氮杂卓衍生物偶联物
|
|
CN113631190A
(zh)
|
2019-03-25 |
2021-11-09 |
第一三共株式会社 |
抗her2抗体－吡咯并苯并二氮杂卓衍生物偶联物
|
|
ES2967879T3
(es)
|
2019-03-25 |
2024-05-06 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
|
|
CA3139180A1
(en)
|
2019-03-27 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
|
TWI862564B
(zh)
|
2019-04-01 |
2024-11-21 |
日商凱依歐姆 生物科學股份有限公司 |
癌治療用醫藥
|
|
AU2020253449A1
(en)
|
2019-04-02 |
2021-11-18 |
William Robert ARATHOON |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
|
AU2020265679A1
(en)
|
2019-04-30 |
2021-12-23 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
US12146160B2
(en)
|
2019-05-14 |
2024-11-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Regulatory T cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
|
US12384834B2
(en)
|
2019-05-28 |
2025-08-12 |
The General Hospital Corporation |
Anti-ApoE antibodies and polynucleotides thereof
|
|
SG11202112429PA
(en)
|
2019-05-29 |
2021-12-30 |
Daiichi Sankyo Co Ltd |
Dosage of an antibody-drug conjugate
|
|
AU2020307471A1
(en)
|
2019-06-24 |
2022-01-27 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
|
|
EP4008350A4
(en)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
|
|
CA3147735A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
WO2021019706A1
(ja)
|
2019-07-31 |
2021-02-04 |
国立大学法人信州大学 |
Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
|
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ｉｄｏ阻害剤の投与レジメン
|
|
EP4007603A1
(en)
|
2019-08-02 |
2022-06-08 |
CytoDyn Inc. |
Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
|
|
BR112022002579A2
(pt)
|
2019-08-12 |
2022-06-14 |
Biond Biologics Ltd |
Anticorpos contra ilt2 e uso dos mesmos
|
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4034151A1
(en)
|
2019-09-27 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
|
EP4034160A1
(en)
|
2019-09-27 |
2022-08-03 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
|
US20240190961A1
(en)
|
2019-10-25 |
2024-06-13 |
Daiichi Sankyo Company, Limited |
Combination of anti-garp antibody and immunomodulator
|
|
PH12022551166A1
(en)
|
2019-11-15 |
2023-10-02 |
Pliant Therapeutics Inc |
Compositions and methods for activation of integrins
|
|
PH12022551208A1
(en)
|
2019-11-18 |
2023-04-24 |
Janssen Biotech Inc |
Vaccines based on mutant calr and jak2 and their uses
|
|
KR20220127250A
(ko)
*
|
2019-12-10 |
2022-09-19 |
씨씨오에이 테라퓨틱스 (항저우) 컴퍼니 리미티드 |
인간화 항-당단백질 ib알파(gpibalpha) 항체
|
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
|
JP7657230B2
(ja)
|
2020-01-03 |
2025-04-04 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法
|
|
WO2021140173A1
(en)
|
2020-01-10 |
2021-07-15 |
Biouniversa S.R.L. |
Methods and uses for treating fibrotic solid tumors with bags inhibitors
|
|
EP4093513A4
(en)
|
2020-01-24 |
2024-05-08 |
Dana-Farber Cancer Institute, Inc. |
USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
|
|
EP4100525A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
|
IL295515A
(en)
|
2020-02-12 |
2022-10-01 |
Janssen Pharmaceutica Nv |
Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
IL295980A
(en)
|
2020-02-28 |
2022-10-01 |
Brigham & Womens Hospital Inc |
Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
|
|
US20230085883A1
(en)
|
2020-03-03 |
2023-03-23 |
Active Biotech Ab |
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
|
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
AU2021230226B2
(en)
|
2020-03-06 |
2025-06-26 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
PE20240020A1
(es)
|
2020-03-13 |
2024-01-04 |
Janssen Biotech Inc |
Materiales y metodos para la union de siglec-3/cd33
|
|
US20240261424A1
(en)
|
2020-03-30 |
2024-08-08 |
National Cancer Center |
Antibody drug conjugate
|
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
|
EP3889183A1
(en)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
A protein complex comprising an immunocytokine
|
|
EP4132568A1
(en)
|
2020-04-06 |
2023-02-15 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
|
EP4151655A1
(en)
|
2020-05-14 |
2023-03-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
|
|
ES2988406T3
(es)
|
2020-05-19 |
2024-11-20 |
Inst Curie |
Antagonistas de la ruta de CD44/ácido hialurónico para su uso en un método para el tratamiento del síndrome de liberación de citocinas
|
|
CN116133684B
(zh)
|
2020-05-27 |
2025-07-18 |
阿里亚利斯治疗公司 |
抗人nr1抗体衍生物
|
|
JP2023528350A
(ja)
|
2020-05-27 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
|
|
EP4161564A1
(en)
|
2020-06-04 |
2023-04-12 |
Kenjockety Biotechnology, Inc. |
Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
|
TW202216208A
(zh)
|
2020-06-24 |
2022-05-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及atr抑制劑之組合
|
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
|
JP2023539715A
(ja)
|
2020-06-24 |
2023-09-19 |
アストラゼネカ ユーケー リミテッド |
抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
|
|
EP4171654A1
(en)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and cdk9 inhibitor
|
|
WO2021260139A1
(en)
|
2020-06-25 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
BR112023000711A2
(pt)
|
2020-07-17 |
2023-01-31 |
Daiichi Sankyo Co Ltd |
Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
|
|
CA3186675A1
(en)
|
2020-07-20 |
2022-01-27 |
Yasuki KAMAI |
Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
|
|
AU2021317111A1
(en)
|
2020-07-29 |
2023-03-30 |
Janssen Biotech, Inc. |
Proteins comprising HLA-G antigen binding domains and their uses
|
|
RU2764216C1
(ru)
*
|
2020-08-10 |
2022-01-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" |
Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
|
|
KR20230058074A
(ko)
|
2020-08-12 |
2023-05-02 |
비온드 바이오로직스 엘티디 |
Ilt2에 대한 항체 및 이의 용도
|
|
WO2022043315A1
(en)
|
2020-08-24 |
2022-03-03 |
Charité - Universitätsmedizin Berlin |
A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
|
|
US20230321242A1
(en)
|
2020-08-24 |
2023-10-12 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
US20230340149A1
(en)
|
2020-09-07 |
2023-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
|
JP2023545359A
(ja)
|
2020-09-12 |
2023-10-30 |
アストラゼネカ・ユーケイ・リミテッド |
抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法
|
|
AU2021355919A1
(en)
|
2020-10-05 |
2023-05-11 |
Chiome Bioscience Inc. |
Medicine for treating cancer
|
|
CA3195117A1
(en)
|
2020-10-09 |
2022-04-14 |
Jerome Thomas Mettetal Ii |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
CA3198590A1
(en)
|
2020-10-13 |
2022-04-21 |
Rajkumar Ganesan |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
|
EP4232064A1
(en)
|
2020-10-21 |
2023-08-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
C-terminal sparc fragments for treating cancer
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
|
EP4240874A1
(en)
|
2020-11-06 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosis and treating polycystic ovary syndrome (pcos)
|
|
TW202227140A
(zh)
|
2020-11-11 |
2022-07-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物及抗SIRPα抗體之組合
|
|
CN116615250A
(zh)
|
2020-11-12 |
2023-08-18 |
第一三共株式会社 |
通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗
|
|
CR20230244A
(es)
|
2020-11-16 |
2023-07-12 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
|
|
EP4251282A1
(en)
|
2020-11-27 |
2023-10-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
|
CA3203587A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
US20240025985A1
(en)
|
2020-12-09 |
2024-01-25 |
National University Corporation Tokyo Medical And Dental University |
Agent for Preventing or Treating Frontotemporal Lobar Degeneration
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
|
|
MX2023008261A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
|
AU2022208361A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Anti-dll3 antibody-drug conjugate
|
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
KR20230159823A
(ko)
|
2021-02-11 |
2023-11-22 |
넥틴 테라퓨틱스 리미티드 |
Cd112r에 대한 항체 및 이의 용도
|
|
CA3208905A1
(en)
|
2021-02-12 |
2022-08-18 |
Boehringer Ingelheim International Gmbh |
Complement c3 antigen binding proteins
|
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
KR20230165212A
(ko)
|
2021-03-02 |
2023-12-05 |
다나-파버 캔서 인스티튜트 인크. |
적혈구 장애의 치료 방법
|
|
US20240279364A1
(en)
|
2021-03-12 |
2024-08-22 |
Daiichi Sankyo Company, Limited |
Glycan, and method for producing medicine containing glycan
|
|
US20250320308A1
(en)
|
2021-03-12 |
2025-10-16 |
Fibrosys S.R.L. |
Monoclonal antibodies for the treatment of viral infections
|
|
TW202304986A
(zh)
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向cd22及cd79b的抗體
|
|
KR20230160353A
(ko)
|
2021-03-24 |
2023-11-23 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
JP2024513172A
(ja)
|
2021-03-26 |
2024-03-22 |
ヤンセン バイオテツク，インコーポレーテツド |
対らせん状細線維タウに対するヒト化抗体及びその使用
|
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
|
AU2022256455A1
(en)
|
2021-04-14 |
2023-10-12 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
|
AR125398A1
(es)
|
2021-04-22 |
2023-07-12 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-cldn4 / anti-cd137
|
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
CN113361141B
(zh)
*
|
2021-07-11 |
2022-02-18 |
西南石油大学 |
一种dna图谱算法的改进试验方法
|
|
PE20240727A1
(es)
|
2021-08-27 |
2024-04-15 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos
|
|
AU2022347380A1
(en)
|
2021-09-15 |
2024-04-11 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
CA3235358A1
(en)
|
2021-10-18 |
2023-04-27 |
Daiichi Sankyo Company, Limited |
Anti-cd37 antibody-drug conjugate
|
|
US20250129165A1
(en)
|
2021-10-27 |
2025-04-24 |
Imcheck Therapeutics |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
AU2022392822A1
(en)
|
2021-11-18 |
2024-05-02 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
US20250019708A1
(en)
|
2021-11-19 |
2025-01-16 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
US20250381241A1
(en)
|
2021-11-29 |
2025-12-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
JP7235262B1
(ja)
|
2021-12-07 |
2023-03-08 |
国立大学法人大阪大学 |
抗体又はその抗原結合性断片
|
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
|
US12344663B2
(en)
|
2021-12-22 |
2025-07-01 |
Cdr-Life Ag |
Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
|
|
KR20240131370A
(ko)
|
2021-12-22 |
2024-08-30 |
인사이트 코포레이션 |
항-cd19 항체 요법을 위한 치료 패러다임
|
|
IL313929A
(en)
|
2021-12-28 |
2024-08-01 |
Astrazeneca Uk Ltd |
Combination of antibody-drug conjugate and atr inhibitor
|
|
EP4456899A1
(en)
|
2021-12-28 |
2024-11-06 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
|
JPWO2023145844A1
(no)
|
2022-01-27 |
2023-08-03 |
|
|
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
|
JPWO2023167238A1
(no)
|
2022-03-02 |
2023-09-07 |
|
|
|
CN119233986A
(zh)
|
2022-03-02 |
2024-12-31 |
海德堡免疫疗法有限公司 |
包含抗体或者包含含有抗体的Fc部分的含Fc融合蛋白的疫苗
|
|
CN119213128A
(zh)
|
2022-03-09 |
2024-12-27 |
株式会社丘阿德 |
与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
|
|
CA3243774A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti-Glucocorticoid-Induced TNFR-Related Protein (GITR) Antibodies and Their Uses
|
|
CA3255700A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
RATING METHOD FOR ANTI-TROP2 ANTIBODY-DRUG CONJUGATE THERAPY
|
|
JPWO2023210405A1
(no)
|
2022-04-25 |
2023-11-02 |
|
|
|
EP4514391A1
(en)
|
2022-04-27 |
2025-03-05 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
|
JP2025517656A
(ja)
|
2022-05-11 |
2025-06-10 |
第一三共株式会社 |
腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
|
|
US20250304706A1
(en)
|
2022-05-12 |
2025-10-02 |
Astellas Pharma Inc. |
Anti-taa/anti-cd3 multispecific antibody
|
|
KR20250012631A
(ko)
|
2022-05-24 |
2025-01-24 |
다이이찌 산쿄 가부시키가이샤 |
항-cdh6 항체-약물 접합체의 투약
|
|
JPWO2023238869A1
(no)
|
2022-06-07 |
2023-12-14 |
|
|
|
KR20250049569A
(ko)
|
2022-07-15 |
2025-04-11 |
페온 테라퓨틱스 리미티드 |
항체-약물 접합체
|
|
MA71616A
(fr)
|
2022-07-28 |
2025-05-30 |
Daiichi Sankyo Company, Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
|
|
AU2023336004A1
(en)
|
2022-08-29 |
2025-03-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate including mutant fc region
|
|
EP4585601A1
(en)
|
2022-09-09 |
2025-07-16 |
Daiichi Sankyo Company, Limited |
Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
|
|
US20240101718A1
(en)
|
2022-09-28 |
2024-03-28 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
|
CA3266717A1
(en)
|
2022-10-04 |
2024-04-11 |
Institut Jean Paoli & Irene Calmettes |
COMBINATION OF A BTN3A ACTIVATING ANTIBODY, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT INTENDED FOR USE IN THE TREATMENT OF CANCER
|
|
WO2024083162A1
(en)
|
2022-10-19 |
2024-04-25 |
Multitude Therapeutics Inc. |
Antibodies, antibody-drug conjugates, preparations and uses thereof
|
|
JP2025535442A
(ja)
|
2022-10-19 |
2025-10-24 |
マルチチュード・セラピューティックス・インコーポレーテッド |
抗体－薬物コンジュゲート、その調製方法、および、その抗腫瘍への使用
|
|
EP4623931A1
(en)
|
2022-11-25 |
2025-10-01 |
The University of Osaka |
Antibody against hematological cancer
|
|
TW202440169A
(zh)
|
2022-11-30 |
2024-10-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物與dnmt抑制劑之組合
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
CN120958025A
(zh)
|
2022-12-16 |
2025-11-14 |
费恩治疗有限公司 |
针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
|
|
IL321045A
(en)
|
2022-12-22 |
2025-07-01 |
Chiome Bioscience Inc |
Anti-human CX3CR1 antibody
|
|
JPWO2024158047A1
(no)
|
2023-01-27 |
2024-08-02 |
|
|
|
WO2024170505A1
(en)
|
2023-02-13 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases
|
|
CN120813377A
(zh)
|
2023-02-23 |
2025-10-17 |
感应检查疗法公司 |
Btn3a活化抗体和免疫检查点抑制剂的组合
|
|
CN120858176A
(zh)
|
2023-03-07 |
2025-10-28 |
居里研究所 |
Brca相关癌症中的ung/udg抑制
|
|
TW202444423A
(zh)
|
2023-03-14 |
2024-11-16 |
日商第一三共股份有限公司 |
抗cdh6抗體-藥物結合物與vegf抑制劑之組合
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
CN120917143A
(zh)
|
2023-03-29 |
2025-11-07 |
第一三共株式会社 |
抗cd25抗体及抗cd25抗体-药物偶联物
|
|
KR20250173601A
(ko)
|
2023-03-31 |
2025-12-10 |
다이이찌 산쿄 가부시키가이샤 |
항 CDH6 항체-약물 콘주게이트와 HIF-2α 저해제의 조합
|
|
TW202506190A
(zh)
|
2023-04-05 |
2025-02-16 |
日商第一三共股份有限公司 |
利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
|
|
CN121038817A
(zh)
|
2023-04-10 |
2025-11-28 |
第一三共株式会社 |
抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
|
|
WO2024213782A1
(en)
|
2023-04-13 |
2024-10-17 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
TW202442682A
(zh)
|
2023-04-14 |
2024-11-01 |
美商英塞特公司 |
抗ＴＧＦβＲ２／ＰＤ－１雙特異性抗體之用途
|
|
WO2024219442A1
(ja)
|
2023-04-19 |
2024-10-24 |
第一三共株式会社 |
抗体－薬物コンジュゲートと他の薬剤との組み合わせ
|
|
TW202506731A
(zh)
|
2023-04-27 |
2025-02-16 |
法商感應檢查療法公司 |
治療多重抗藥性細菌感染之方法
|
|
AU2024274397A1
(en)
|
2023-05-17 |
2025-11-13 |
Syndax Pharmaceuticals, Inc. |
Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
|
|
WO2025003461A1
(en)
|
2023-06-30 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of metabolic disorders
|
|
WO2025006737A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
|
|
WO2025024272A1
(en)
|
2023-07-23 |
2025-01-30 |
Incyte Corporation |
Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
|
|
WO2025034542A1
(en)
|
2023-08-04 |
2025-02-13 |
Cornell University |
Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025040820A1
(en)
|
2023-08-23 |
2025-02-27 |
Granular Therapeutics Limited |
Anti-cd203c antibody conjugates and uses thereof
|
|
WO2025056739A1
(en)
|
2023-09-14 |
2025-03-20 |
Medizinische Universität Innsbruck |
Enhancement of car-t cell efficacy by inhibiting nr2f6
|
|
WO2025068157A1
(en)
|
2023-09-25 |
2025-04-03 |
Stromacare |
COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
|
|
WO2025068180A1
(en)
|
2023-09-25 |
2025-04-03 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of cancer by targetting cancer - associated fibroblasts
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025088496A1
(en)
|
2023-10-24 |
2025-05-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
|
|
EP4563586A1
(en)
|
2023-11-28 |
2025-06-04 |
Université Paris Cité |
New inhibitors of lrrk2/pp1 interaction
|
|
TW202535479A
(zh)
|
2023-12-05 |
2025-09-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
|
|
WO2025122695A1
(en)
|
2023-12-06 |
2025-06-12 |
Incyte Corporation |
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors
|
|
EP4570262A1
(en)
|
2023-12-15 |
2025-06-18 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Chimeric antigen receptor directed against the chemokine receptor ccr7
|
|
WO2025147575A1
(en)
|
2024-01-06 |
2025-07-10 |
Generate Biomedicines, Inc. |
Anti-il-13 antibodies and methods of use thereof
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025176777A1
(en)
|
2024-02-20 |
2025-08-28 |
Institut Curie |
Dut inhibition in homologous recombination deficiency cancer
|
|
WO2025176860A1
(en)
|
2024-02-23 |
2025-08-28 |
Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts |
Dual chimeric antigen receptor construct targeting cea and epcam
|
|
FR3159967A1
(fr)
|
2024-03-06 |
2025-09-12 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Anticorps neutralisant à haute affinité dirigé contre la ricine
|
|
WO2025215252A1
(en)
|
2024-04-12 |
2025-10-16 |
Ensocell Ltd |
Therapeutic agents and methods for targeting myeloid cell subtypes
|
|
EP4635980A1
(en)
|
2024-04-19 |
2025-10-22 |
Medigene Immunotherapies GmbH |
Uni-tags specific antibody
|
|
US20250325664A1
(en)
|
2024-04-22 |
2025-10-23 |
Incyte Corporation |
Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
|
|
WO2025224050A1
(en)
|
2024-04-22 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of patients suffering from hypomelanosis of ito
|